FCGR3A and neoplasm: Notably, CD16-triggered ADCC and phagocytosis, performed by NK cells and macrophages, respectively, are among the main immune-dependent mechanisms by which tumor-targeting therapeutic mAbs mediate tumor cell killing [6–8].